11
Jun
2010
Posted in I - Series B, Q - 2Q10, R - WEST, X - Device (Diagnostic), X - Oncology, XX - CA
Veracyte (San Francisco, CA) a clinical-stage molecular diagnostics company focused on non-small cell lung cancer and thyroid cancers, closed a $28M Series B financing. Participants include Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures.